CTST - CannTrust Holdings Inc.

NYSE - NYSE Delayed Price. Currency in USD
+0.0063 (+0.75%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close0.8378
Bid0.8500 x 800
Ask0.8900 x 1100
Day's Range0.8300 - 0.9000
52 Week Range0.7500 - 10.1700
Avg. Volume2,315,090
Market Cap118M
Beta (5Y Monthly)3.88
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CannTrust Holdings Inc. (CTST) Outpaces Stock Market Gains: What You Should Know

    CannTrust Holdings Inc. (CTST) Outpaces Stock Market Gains: What You Should Know

    CannTrust Holdings Inc. (CTST) closed the most recent trading day at $0.84, moving +0.75% from the previous trading session.

  • Benzinga

    NYSE Warns CannTrust Is No Longer In Compliance With Listing Rules

    CannTrust Holdings Inc. (NYSE: CTST)(TSX:TRST) said Tuesday afternoon it was notified by the New York Stock Exchange on Monday that it's no longer in compliance with the NYSE’s listing standard rules due to CannTrust’s share price falling below the set threshold. The NYSE demands the average closing price of a listed company’s shares to be a minimum of $1.00 per share for 30 consecutive trading days. On Monday, CannTrust’s 30 trading-day average closing price was 97 cents.

  • PR Newswire

    CannTrust Receives Continued Listing Notice from the NYSE

    CannTrust Holdings Inc. ("CannTrust" or the "Company", TSX: TRST, NYSE: CTST) announced today that on December 9, 2019, the Company received written notification from the New York Stock Exchange (the "NYSE") that CannTrust is no longer in compliance with the NYSE's continued listing standard rules because the per share trading price of the Company's common shares has fallen below the NYSE's share price rule. The NYSE requires the average closing price of a listed company's common shares to be at least US $1.00 per share over a consecutive 30 trading-day period. As of December 9, 2019, the 30 trading-day average closing price of the Company's common shares was US $0.97.

  • CNW Group

    CannTrust Provides Default Status Report and Other Updates

    VAUGHAN, ON , Dec. 5, 2019 /CNW/ – CannTrust Holdings Inc. ("CannTrust" or the "Company", TSX: TRST, NYSE: CTST) today is providing a status update in accordance with its obligations under the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders ("NP 12-203"), which require the Company to provide bi-weekly updates until such time as the Company is current with its filing obligations under Canadian securities laws. As previously announced, the Company is subject to a management cease trade order ("MCTO") issued by the Ontario Securities Commission. The MCTO prohibits the directors and executive officers of the Company from trading in or acquiring securities of the Company until two full business days after the Company files an interim financial report for the three and six month periods ended June 30, 2019 , an interim management's discussion and analysis for the corresponding period and certifications of interim filings.

  • CNW Group

    CannTrust Provides Update Regarding TSX Listing

    VAUGHAN, ON , Nov. 26, 2019 /CNW/ - CannTrust Holdings Inc. ("CannTrust" or the "Company", TSX: TRST, NYSE: CTST) today announced that the Toronto Stock Exchange ("TSX") has advised the Company that it intends to review CannTrust's eligibility for continued listing of the Company's common shares on the TSX, pursuant to Part VII of the TSX Company Manual.

  • Marijuana Stocks Are Tumbling — Are Any Good Buys Right Now?
    Investor's Business Daily

    Marijuana Stocks Are Tumbling — Are Any Good Buys Right Now?

    Are marijuana stocks on U.S. exchanges a good buy now? The marijuana industry gets a lot of hype, but look past the smoke and analyze pot stocks on their fundamentals and technicals.

  • Benzinga

    Cannabis Countdown: Top 10 Marijuana Stock News Stories Of The Week

    Cannabis Countdown: Top 10 Marijuana Stock News Stories of the Week Welcome to the  Cannabis Countdown . In this week’s rendition, we’ll recap and countdown the top 10 marijuana stock news stories for ...

  • Sell Any Bounce in Hexo Stock After Massive Earnings Flop

    Sell Any Bounce in Hexo Stock After Massive Earnings Flop

    If you own Hexo (NYSE:HEXO) stock, you're probably wondering if it can get any worse. Hexo's share price was recently down 80% from its April peak. Just since the beginning of October, HEXO stock had lost more than half of its remaining value. Shares recently tanked below the $2 mark following lousy earnings both at Hexo and at rivals such as Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB). This week, though, HEXO stock has put in a substantial turnaround, moving from below $2 back to more than $2.50 per share.Source: Shutterstock Was that the final bottom in HEXO stock? With folks looking past last quarter's earnings, and with the tax-loss selling season winding down, is this the time to load up on the shares?While the bounce in HEXO stock may continue for now, for longer-term investors, sadly, there's even more downside ahead for Hexo. Here's why.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Disastrous Quarterly ResultsHexo's earnings results at the end of October gave investors little reason for optimism. It's no surprise that traders have dumped HEXO since the company announced earnings.Looking merely at revenues, things might not seem that bad. Overall corporate revenues jumped from 13 million CAD ($9.79) to 15.4 million CAD sequentially. That leaves out a key fact, though. The merger with Newstrike closed this quarter. Excluding those revenues, Hexo's sales would have been less than 13 million CAD , making a second consecutive quarter of falling revenues. * 5 Lottery Stocks With Triple-Digit Upside This makes sense, as Hexo isn't a leader in the medical cannabis space … yet. Meanwhile, prices are plunging in the recreational space as inventory vastly exceeds demand. This led to a particularly unfortunate situation where Hexo purchased inventory earlier this year from outside parties, and is now forced to resell that supply at a loss.This quarter's earnings confirm that Hexo's business strategy hasn't worked out any better than its peers. And there's no near-term turnaround in the works.The company lowered Q1 2020 guidance and pulled its previous full-year 2020 guidance altogether. Think about it: With even the likes of Aurora and Canopy struggling mightily, why buy Hexo? Shrinking To SurviveUntil recently, Hexo had been pitching investors an incredible growth story. Things have changed dramatically though; now Hexo is retrenching.They're reducing the levels of operations at their home facility in Quebec. And they're suspending grow operations at their Niagara facility which they just finished acquiring from Newstrike. On top of that, they're laying off several hundred employees. Again, none of this is unique to Hexo, rather, it's a similar refrain across the cannabis space. But it shows questionable planning on Hexo's part; their strategic moves simply haven't panned out throughout the year.The Newstrike deal in particular has raised more concern due to an admission that some unlicensed cannabis was inadvertently grown there. As Hexo disclosed in a recent press release:On July 30, 2019, shortly after the Newstrike Brand Ltd. acquisition closed, HEXO discovered that cannabis was being grown in Block B, which was not adequately licensed. HEXO management immediately ceased cultivation and production activities in the unlicensed space. The Company notified Health Canada instantly, and the regulator was satisfied with HEXO management's corrective actions. For now, it appears this won't be a major issue for HEXO stock, particularly since they are dialing back growing operations anyway. However, don't forget what happened to CannTrust (NYSE:CTST) earlier this year; the regulators can hit hard if they sense any more weakness in compliance. Hexo Let Investors Down With Optimistic GuidanceWe know the marijuana industry is going through a tremendous struggle at the moment. We can forgive a management team for doing its best and coming up short of expectations given the incredible headwinds in the industry right now. It's harder, however, to look the other way if management gives wildly promotional forward guidance and then whiffs by a mile. * 9 Tantalizing Dividend Stocks for 2020 Heading into the October quarter, management had suggested that the company would bring in more than 30 million CAD in revenues. The actual number was only half of what it had expected. And for 2020, Hexo had been projecting 400 million CAD in sales. Now it is struggling to grow revenues at all. Needless to say, with the most recent quarterly results coming in at just 15.4 million CAD, the company is annualizing at about 60 million CAD -- there's no reasonable path to 400 million CAD in sales in the near future, and anyone that bought HEXO stock on that previous guidance has got to be extremely frustrated now. HEXO Stock VerdictThe HEXO stock story isn't over yet. The company, with its recent capital raise, still has money to keep on going for quite awhile yet. And while management's recent cut to guidance was devastating, there is still a potential growth story here.Sure, it'd be wise to scale back your expectations after what we just saw. Still, the company has several irons in the fire, including its joint venture with Molson Coors (NYSE:TAP) that could give it a big leg up in grabbing the cannabis beverages market. I've said it before, I'd much rather own TAP stock than HEXO stock if that's the angle you're interested in. If it works out, both companies will prosper, if it flops, Molson Coors still has the beer business to keep paying the bills. Regardless, it's a potential catalyst that could revitalize the HEXO stock price.At the end of the day, though, Hexo is still selling for a more-than $650 million market cap. That's really high for a company that is losing lots of money, has seen revenue growth stall out and whose management just blew its credibility with its previous revenue forecast.I know HEXO stock may seem cheap given the sub-$2.50 share price. But even at this level, it's still baking in a lot of optimism that the company will get back on track in 2020. I'm not so confident of that.At the time of this writing, Ian Bezek owned TAP stock. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Marijuana Penny Stocks That Have Ridiculous Possibilities * 7 High-Yield ETFs to Buy Now * 4 Dow Jones Industrial Average Stocks to Sell The post Sell Any Bounce in Hexo Stock After Massive Earnings Flop appeared first on InvestorPlace.

  • PR Newswire

    CannTrust Provides Default Status Report

    VAUGHAN, ON, Nov. 21, 2019 /PRNewswire/ - CannTrust Holdings Inc. ("CannTrust" or the "Company", TSX: TRST, NYSE: CTST) today is providing a status update in accordance with its obligations under the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders ("NP 12-203"), which require the Company to provide bi-weekly updates until such time as the Company is current with its filing obligations under Canadian securities laws. As previously announced, the Company is subject to a management cease trade order ("MCTO") issued by the Ontario Securities Commission. The MCTO prohibits the directors and executive officers of the Company from trading in or acquiring securities of the Company until two full business days after the Company files an interim financial report for the three and six month periods ended June 30, 2019, an interim management's discussion and analysis for the corresponding period and certifications of interim filings.

  • 7 Marijuana Penny Stocks That Have Ridiculous Possibilities

    7 Marijuana Penny Stocks That Have Ridiculous Possibilities

    You don't have to look too far to recognize the devastation that has occurred among marijuana stocks. Due to generally disappointing financial performances, the sector has been awash in red ink. Unfortunately, investors are losing patience with this chronically losing market, which has -- unsurprisingly -- affected marijuana penny stocks disproportionately.Naturally, I understand if someone is hesitant to dive into this sector, irrespective of the discount. We can talk all day about the transformative potential of legal cannabis, and I've done exactly that. But Wall Street has nervously eyeballed financial viability. Without any of the major players stepping up to the plate, cannabis investments, especially marijuana penny stocks, have incurred volatility.But if you're willing to absorb the bruises inherent in "botanical" companies, you may want to reconsider marijuana stocks. First, several green competitors rebounded on Tuesday on the announcement of a proposed Congressional bill to remove "criminal prohibitions against marijuana at the federal level."InvestorPlace - Stock Market News, Stock Advice & Trading TipsIf successful, this would represent a huge lift for both the major cannabis players and marijuana penny stocks. Currently, the Agriculture Improvement Act of 2018, colloquially known as the farm bill, federally legalizes industrial hemp and hemp-derived products. Specifically, this means that hemp or hemp-derived cannabis products like cannabidiol (CBD) cannot contain more than 0.3% tetrahydrocannabinol (THC) content.A second upshot for marijuana stocks is that Americans have a growing distrust for the medical system. That's not surprising, considering major pharmaceutical firms' involvement in the raging opioid crisis. People are looking for true, naturally sourced therapies and cannabis offers a viable pathway. * 7 Killer Stocks No One Knows About With that, let's take a look at seven compelling marijuana penny stocks: cbdMD (YCBD)Source: Shutterstock Before I get into it, I should caveat that cbdMD (NYSEAMERICAN:YCBD) isn't a name most folks would consider belonging among key marijuana penny stocks to buy. Furthermore, cbdMD does not specialize in marijuana products. Instead, they focus on broad spectrum CBD -- products that contain CBD, other cannabinoids and essential oils (terpenes), but zero THC.This last point is especially important for YCBD stock because cbdMD has endorsement deals with several pro-athletes. Arguably, the most well known is two-times Masters champion Bubba Watson. As Watson relayed in an interview, he needed a product that would help with the aging process. He also required a product that would allow him to compete professionally without pinging positive for a drug test.Another reason why YCBD stock deserves a top billing is that cbdMD is headquartered in the U.S. And the American market is wide open for a company to establish a CBD brand, according to cbdMD CEO Marty Sumichrast. Thanks to a comprehensive and effective product portfolio along with key endorsements, YCBD stock is a name you shouldn't ignore. Hexo (HEXO)Source: Shutterstock Among the worst hit marijuana stocks, Hexo (NYSE:HEXO) was trading within the respectable $4 price range in late summer of this year. However, a rash of poor fiscal performances in the sector substantially hurt HEXO stock. And specific to the underlying company, the growing losses in net income have worried investors.As a result, HEXO is now counted among the worst hit marijuana penny stocks. Still, if you've got an iron stomach, I believe this embattled firm has serious upside potential.For one thing, management has earned respect for its forthrightness regarding its unlicensed cannabis production incident. Due to an oversight, Hexo mistakenly produced cannabis in an unlicensed area. However, unlike CannTrust (NYSE:CTST), management reported the incident to governing agency Health Canada. Optically, despite an unfortunate error, I think it is a good look for HEXO stock because of the honesty involved. * 10 Best High-Growth Stocks to Buy for Young Investors Second, Hexo has a joint venture with Molson Coors Brewing (NYSE:TAP) to produce CBD-infused beverages. Experts peg this market to hit over $1 billion by 2022, presenting an opportunity for HEXO stock. CV Sciences (CVSI)Source: Kimberly Boyles / Shutterstock.com Under the best of circumstances, equity shares of small pharmaceutical companies are subject to extreme volatility. Logically, then, marijuana penny stocks that focus on cannabis-based drugs are just as unpredictable, if not more so. And that's the case with CV Sciences (OTCMKTS:CVSI) and CVSI stock.Back when the weed market was still fresh, companies like CV Sciences experienced dramatic surges in valuation. However, with the Street demanding hard results and not merely tantalizing narratives, the cannabis investment sector crumbled.Still, CVSI stock makes a compelling case for itself if you're willing to accept the wildness in its pricing dynamic. One of the company's drugs is a synthetic CBD formulation designed to curb smokeless tobacco use and addiction. With the vaping crisis becoming one of the hot topics earlier this year, CV Sciences' products have incredible relevancy. Cannabis Sativa (CBDS)Source: Shutterstock Like many marijuana penny stocks, Cannabis Sativa (OTCMKTS:CBDS) started off with great promise thanks to its multi-varied brands and businesses. For instance, the company opened up its first "hi Brand International" dispensary in Portland, Oregon. It's also seeking opportunities for expansion into green-friendly states.That said, one of the more intriguing businesses connected to CBDS stock is the skincare market. According to retail cannabis market experts, the CBD skincare market will likely reach $1.7 billion by 2025. That might not sound like a groundbreaking number. However, considering that Cannabis Sativa only made half-a-million dollars last year, this could be a huge prospect for CBDS stock. * These 10 Stocks to Buy Make the Perfect 'Retirement' Portfolio Moreover, speculators should consider the broader implications. Major marijuana stocks, such as Cronos Group (NASDAQ:CRON), are entering the U.S. CBD market via acquisitions like the Lord Jones deal. Of course, Lord Jones is a big CBD skincare brand. Thus, CBDS stock is at least fundamentally moving in the right direction. MariMed (MRMD)Source: Shutterstock If there's one phrase to describe marijuana stocks, it's that this industry represents the perpetual clash between theory and reality. In theory, legal cannabis opened up the door to previously untappable revenue streams. But in reality, the industry suffered from unexpected supply chain issues, stymieing an otherwise unprecedented breakthrough.However, this theory-versus-reality conflict also benefits MariMed (OCTMKTS:MRMD) and MRMD stock. Primarily, MariMed operates as an administrative and operational advisor for the burgeoning cannabis industry. While legalization in North America has brought initial enthusiasm, cannabis-based enterprises are incredibly tough to get up and running. Here, MariMed plays the role of expert consultant, navigating clients away from common pitfalls toward higher probabilities of success.Despite the obvious need for the company's services, that hasn't stopped MRMD stock from turning volatile. In fact, today, it's firmly in the territory of marijuana penny stocks. Still, shares appeared to have stabilized since mid-October, tempting the contrarian approach. MedMen Enterprises (MMNFF)Source: Shutterstock It's almost tragic what happened to MedMen Enterprises (OTCMKTS:MMNFF) recently. Just days ago, MMNFF stock was trading above the all-too-critical $1 threshold. But with the ugly realization that the underlying company could face bankruptcy, shares tumbled below that threshold. Now, it's on this list of very speculative marijuana penny stocks.But can it eventually join the ranks of "regular" marijuana stocks? I'm going to be blunt: MMNFF stock is now one of the riskiest names in the cannabis markets. On the flipside, it does have tremendous upside potential because of this overwhelming risk.In my interview with cbdMD's CEO Marty Sumichrast, he articulated the concept of cannabis branding. When it comes to the retail space, I can't think of a cleaner and more professional brand than MedMen Enterprises. It doesn't try to be an over-the-top weed distributor. Instead, they're focused on quality products and excellent customer service. * 7 High-Yield ETFs to Buy Now Will this be enough to save MMNFF stock? Undoubtedly, this is a gamble, but an interesting one. Diego Pellicer Worldwide (DPWW)Source: Shutterstock If you're looking for the "ultimate" in marijuana penny stocks, then treat yourself to Diego Pellicer Worldwide (OTCMKTS:DPWW). Funny, but true story: I didn't even know about this company's existence until an InvestorPlace reader named Anthony reached out to me and asked me about it. Curious, I researched DPWW stock and I must say it's an intriguing concept.Generally speaking, legal cannabis retailers fall under two camps: those that emphasize the "street image" of the cannabis plant and businesses that cater to therapeutic use. However, Diego Pellicer introduces a third option: premium, luxury-themed cannabis products.Under ideal circumstances, DPWW stock might work out. Making cannabis isn't exactly rocket science. Thus, with supply rising, industry players need a distinguishing brand. Diego Pellicer has that in droves.What it doesn't have, though, is market credibility. DPWW stock currently trades at less than 2 cents. You've been warned.As of this writing, Josh Enomoto is long YCBD, HEXO, and MRMD. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Best Consumer Stocks to Buy Before Black Friday * 9 Tantalizing Dividend Stocks for 2020 * 5 Lottery Stocks With Triple-Digit Upside The post 7 Marijuana Penny Stocks That Have Ridiculous Possibilities appeared first on InvestorPlace.

  • CBD beverage founder: 'I want to be regulated'
    Yahoo Finance

    CBD beverage founder: 'I want to be regulated'

    Not nearly enough legislative ink has been spilled over the booming CBD industry, according to Benjamin Witte. 

  • InvestorPlace

    10 Medical Marijuana Stocks to Cure Your Portfolio

    [Editor's note: "10 Medical Marijuana Stocks to Cure Your Portfolio" was previously published in October 2019. It has since been updated to include the most relevant information available.] Invariably, no other investment class generates as much interest and controversy as marijuana stocks. Within a generation, public sentiment toward legalization shifted dramatically from strongly opposed to mostly supportive. This is largely due to demographics, as the more progressive millennials replace older Americans in positions of influence.Additionally, marijuana stocks represent a viable economic channel that can help bridge the gap for many states' financial issues. For instance, green-friendly Colorado enjoys significant tax revenues from its botanical industry. I don't see this trend changing for the worse anytime soon, as awareness and popularity is only increasing.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOf course, cannabis isn't without its controversies. Primarily, the federal government classifies marijuana as a Schedule I drug, putting it on par with hardcore narcotics like cocaine. Thus, no matter how liberal some states become toward their agricultural ambitions, the specter of federal oversight and crackdowns keeps many entrepreneurs and businesses away.However, we have one critical exception to the rule: marijuana stocks that specialize in medicinal and therapeutic benefits. For one thing, medical cannabis mitigates the stereotypical image of potheads and general no-gooders. Plus, people experiment with pharmaceuticals all the time. Why not allow these same patients the choice for natural alternatives? * 7 Retail Stocks to Avoid for the Holidays More critically for marijuana stocks, the medicinal aspect offers the best chance for international acceptance. Currently, very few jurisdictions allow recreational weed. Given the abundance of traditional and conservative nations, a green world is unlikely. But as Thailand and South Korea demonstrated, medical cannabis is a much easier sell.As a result, you want exposure not just to marijuana stocks, but also to the therapeutic element. Here are 10 names to consider: AbbVie (ABBV)Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:ABBV) isn't the first name you think about. One of the healthcare sector's blue chips, ABBV stock has soared on its vast therapeutic pipeline.We're talking mainstream solutions for common ailments and diseases like arthritis and plaque psoriasis.Still, AbbVie maintains some botanical credibility with its Marinol therapy. A synthetic cannabis-based drug, Marinol addresses chemotherapy-related side effects, such as vomiting or nausea. In addition, it helps restore appetite among AIDS patients.Of course, you should note that Marinol isn't among AbbVie's top-selling products. Therefore, you're only getting limited exposure to cannabis with ABBV stock. But based on the extreme volatility of marijuana stocks, that isn't such a bad gig. Emerald Health Therapeutics (EMHTF)Source: Shutterstock Not that I would know, but growing cannabis allegedly isn't rocket science.With the right conditions, the right equipment and a reasonable car, anyone can grow their stash. But cultivating the plant so that it addresses specific ailments and symptoms? That takes real effort, which is where Emerald Health Therapeutics (OTCMKTS:EMHTF) comes in.Rather than just pumping out the green stuff, Emerald deliberately seeks out the strains most effective in addressing patients' needs. The company provides a wide selection of strains, which range in weight, tetrahydrocannabinol (THC) content, and cannabidiol (CBD) strength. Their impressive portfolio should lift EMHTF stock over the long run, as interest in CBD products accelerates. * 7 Retail Stocks to Avoid for the Holidays It's important to be careful with pot stocks, though. On a year-to-date basis, EMHTF stock is down 75%. While all cannabis stocks suffer volatility risk, Emerald's concentration on medicinal weed should help mitigate downside pressure. Aurora Cannabis (ACB)Source: Shutterstock I've spent a lot of time discussing Aurora Cannabis (NYSE:ACB), and I don't mean to keep double-dipping into this company. Still, I keep going back for a reason: ACB stock is an excellent play within the medical-marijuana market.A key factor in my bullishness for Aurora is its management team. In my view, they're making smart decisions through their acquisitive strategy.Rather than merely focusing on outright capacity, they're looking out over the horizon. Aurora's buyout of Whistler Medical Marijuana gave the organization significant leverage in medical cannabis due to Whistler's extensive genetics bank.Furthermore, ACB stock is a strong performer. In the beginning of the year, shares skyrocketed roughly 70% before plummeting. It's down 28% this year. The inevitable correction should be only temporary. Among marijuana stocks, Aurora is exceptionally well-positioned for sustainable growth. Cronos Group (CRON)Source: Shutterstock One of the top names among major marijuana stocks, Cronos Group (NASDAQ:CRON) naturally attracts a lot of attention. This time, though, they're attracting the wrong kind.Prior to its earnings report for the second quarter, I worried about the company's revenue target.Hit or exceed it, and management can stave off criticism, but speculators looking for a discounted price may want to put CRON stock back on their radar. After concerns about vaping safety hit the news, Cronos has shed all of this year's gains and more, as it's down nearly 24% YTD. * 7 Retail Stocks to Avoid for the Holidays Plus, Cronos has international legitimacy among medicinally focused cannabis stocks. Featuring partnerships and joint ventures across five continents, the company is ahead of the game. CannTrust (CTST)In business, even the green kind, you can't get ahead of yourself. So while lucrative opportunities exist in the international sector, CannTrust (NYSE:CTST) remains firmly committed to winning its native Canadian market.At the same time, CannTrust can't afford to ignore the rest of the world. Although Canada becoming the first G7 nation to legalize recreational weed generated headlines, our northern neighbors alone can't support this burgeoning industry.Therefore, management has focused on the growth and capacity narrative to compete effectively at home and, later, abroad.To achieve the second leg of this journey, CannTrust teamed up with Denmark's Stenocare to distribute medical cannabis products in that country.It also inked a partnership with an Australian firm for similar distribution arrangements. While it's not the most common name among marijuana stocks, CTST stock provides a risky, but viable, opportunity. Innovative Industrial Properties (IIPR)Most marijuana stocks focus on the industry's front face; namely, production. As I mentioned earlier, marijuana isn't that difficult to grow. So long as you have the green light legally, the physical barrier to entry is relatively short.But the real challenge, though, is finding a consistent source of financing. This is where Innovative Industrial Properties (NYSE:IIPR) lends a helping hand.Despite momentum toward legalization, several financial institutions shy away from cannabis ventures.Innovative Industrial plugs the gap, offering critical capital through its leaseback business model. * 7 Retail Stocks to Avoid for the Holidays Thanks to the company's tremendous utility, IIPR stock has lit up the markets. Shares are currently up more than 75% YTD. Technically, IIPR may have gotten a bit overheated. That said, I wouldn't get too greedy looking for the perfect entry point. Innovative Industrial levers a proven business model that is only increasing in relevancy. Terra Tech (TRTC)Everyone recognizes cannabis stocks for two things: their incredible potential and their equally incredible volatility. Unfortunately, stakeholders of medical-cannabis producer Terra Tech (OTCMKTS:TRTC) find themselves in the latter category.So far this year, TRTC stock is down around 53%.And the bad news doesn't end there. Terra Tech only had $1.9 million of cash at the end of Q2.So why take a bet on TRTC stock? First, its vertically integrated organization may facilitate significant efficiencies as political momentum increases. Second, I dig their leadership team. The head execs are experts in finance, which should prove beneficial in properly navigating TRTC across choppy waters. Charlotte's Web (CWBHF)Source: Shutterstock When most people look at Charlotte's Web (OTCMKTS:CWBHF), they're thinking that they missed the boat. After all, CWBHF stock jumped 78% at the beginning of this year.From the opening price this year, however, Charlotte's Web shares are down over 10%.As much as I love marijuana stocks, I'm fairly certain that this cannabis firm is due for a further pullback. But once that occurs, I wouldn't waste too much time squabbling over the granularity.Instead, I'd consider what our own Matt McCall had to say. Thanks to the popularity of CBD, Charlotte's Web's CBD-based products could be distributed across mainstream retail channels. * 7 Retail Stocks to Avoid for the Holidays Unquestionably, such an event would launch CWBHF stock into the stratosphere. Moreover, because most CBD products contain no trace of THC, they don't fall under severe federal guidelines. Therefore, don't get too greedy looking for an ideal price point when CWBHF corrects. Cannabis Science (CBIS)On paper, Cannabis Science (OTCMKTS:CBIS) represents the next evolution among cannabis stocks: pharmaceutical firms that devote their time and research exclusively toward medical marijuana.Not only that, this is a much-needed development that could lift CBIS stock, as well as the entire botanical industry.For decades, people unquestionably trusted the mainstream healthcare and pharmaceutical network.However, the rapidly escalating opioid crisis has proven that well-intentioned medical professionals can lever a tragic impact. One of the underlying causes of this crisis is the addictiveness of prescribed medicines.Organizations like Cannabis Science can potentially mitigate this situation with naturally sourced therapies free of psychoactive side-effects. That's the allure of CBIS stock. However, shares trade for $0.0049 cents a pop, so this is only for the risk-tolerant. GW Pharmaceuticals (GWPH)Source: Shutterstock On a surface level, GW Pharmaceuticals (NASDAQ:GWPH) brings a lot of positives to the table. As pioneers among medicinally-concentrated marijuana stocks, they lever substantial credibility.Their Sativex drug for addressing symptoms associated with multiple sclerosis achieved better-than-expected results. This only encourages other companies to pursue cannabis-based therapies for many other diseases. * 7 Retail Stocks to Avoid for the Holidays As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Sell Before They Roll Over * 5 Beaten-Up Stocks to Buy That Could Be Saved By An Acquisition * 4 Startup Stocks Getting Smashed The post 10 Medical Marijuana Stocks to Cure Your Portfolio appeared first on InvestorPlace.

  • CannTrust (CTST) to Report Q3 Earnings: What's in Store?

    CannTrust (CTST) to Report Q3 Earnings: What's in Store?

    On CannTrust's (CTST) third-quarter earnings call, investor focus will be on the company's efforts to regain licenses for producing and selling cannabis.

  • Zacks

    Marijuana Stocks to Buy or Avoid in November

    We highlight three marijuana stocks that look like solid bargains, while one in particular should be avoided in the near future.

  • Benzinga

    Kaden Resigns From CannTrust Board; Search Underway For New Directors, Permanent CEO

    CannTrust Holdings Inc. (TSX:TRST) (NYSE: CTST) announced Monday that John Kaden is resigning from its board of directors. The company is renewing its board following a Special Committee independent investigation and the submission of a remediation plan to Health Canada. Health Canada found the company to be in noncompliance earlier this year and later suspended its cannabis license.